赴湖境之约，享松弛假日 兴隆湖自然生活季正式启幕
本报讯 金秋国庆，举国同庆。10月1日，由四川天府新区文创和会展局主办的兴隆湖自然生活季，在兴隆湖浮响书店旁启幕。活动依托兴隆湖优良湖域生态条件，设置林野文创市集、主题文艺展演、松弛运动会、林间工作坊..... (93)人阅读时间：2026-10-01
From Movie Sets to Experimental Games: Meet the Craftspeople Shaping Genshin Impact's Miliastra
HoYoverse gamescom Event Celebrates the 50+ Creators Behind Popular User-Generated Content Experiences in Genshin Impact's UGC Module
Templafy 报告发现：95% 的知识工作者在 AI 生成文档达到商用标准前仍需手动编辑
近半数美国与英国员工表示，审阅 AI 生成的商业文档后，实际节省的时间所剩无几
Templafy Report Finds 95% of Knowledge Workers Edit AI-Generated Documents Before They’re Business-R
Nearly half of U.S. and U.K. workers say reviewing AI-generated business documents can leave little actual time saved
Manifests Ireland Grows Customs Operations from 20,000 to 2 Million Annual Declarations with Descart
LONDON and ATLANTA , Oct. 01, 2026 (GLOBE NEWSWIRE) -- The Descartes Systems Group (Nasdaq:DSGX) (TSX:DSG), the global leader in uniting logistics-intensive businesses in commerce, announced that cust..... (86)人阅读时间：2026-10-01
深耕育才固本 同心奔赴未来——菜百股份“金色工程—金色种子”人才发展项目正式启幕
为深入贯彻党的二十大关于深入实施人才强国战略部署，严格落实党管人才、人才强企工作要求，紧扣“十五五”谋篇布局关键阶段的人才队伍建设核心任务，近日，菜百股份“金色工程-金色种子”人才发展项目开课仪式隆..... (88)人阅读时间：2026-10-01
New Travel Industry Coalition Calls for EU Digital Omnibus to Enable Secure, Seamless Biometric Jour
Coalition seeks an effective and fair EU approach for responsible biometric travel to protect passenger choice, privacy and fundamental rights.
New Travel Industry Coalition Calls for EU Digital Omnibus to Enable Secure, Seamless Biometric Jour
Coalition seeks an effective and fair EU approach for responsible biometric travel to protect passenger choice, privacy and fundamental rights.
Boehringer Ingelheim's survodutide achieves up to 13.1% weight loss in new Phase III trial
Boehringer Ingelheim's survodutide achieves up to 13.1% weight loss in new Phase III trial, alongside significant improvements in glycemic control in people with obesity and type 2 diabetes
Boehringer Ingelheim's survodutide achieves up to 13.1% weight loss in new Phase III trial
Boehringer Ingelheim's survodutide achieves up to 13.1% weight loss in new Phase III trial, alongside significant improvements in glycemic control in people with obesity and type 2 diabetes
